• Home
  •  / PharmaEssentia

PharmaEssentia

  • RevenueNT$656.5 MFY, 2021
  • Market CapitalizationNT$135.2 B2022-06-22

OverviewSuggest Edit

PharmaEssentia is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases. Its lead compound is ropeginterferon alfa-2b, an interferon for myeloproliferative neoplasms and hepatitis. The company also develops treatments for gastric, gastro-esophageal, esophageal, and breast cancer, as well as psoriasis.
TypePublic
Founded2003
HQTWMap
Websitepharmaessentia.com
Employee Ratings4.5

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2019)190
Revenue (FY, 2021)NT$656.5 M(+18%)
Share Price (Jun 2022)NT$489(+2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at PharmaEssentia

Kochung Lin

Kochung Lin

Founder and CEO
Albert Qin

Albert Qin

Chief Medical Officer
Craig Zimmerman

Craig Zimmerman

Vice President of US Operations
Yi-Wen Huang

Yi-Wen Huang

Senior Director, Medical Research & Clinical Operation
Chaosheng Cheng

Chaosheng Cheng

Senior Director of Biologics Manufacturing
Show more

PharmaEssentia Office Locations

PharmaEssentia has offices in Burlington and Shinjuku City
Shinjuku City, JP
2-chōme-5-12 Shinjuku
Burlington, MA, US
35 Corporate Dr #325
Show all (5)

PharmaEssentia Financials and Metrics

PharmaEssentia Revenue

PharmaEssentia's revenue was reported to be NT$656.51 m in FY, 2021
TWD

Revenue (Q1, 2022)

251.7m

Gross profit (Q1, 2022)

133.2m

Net income (Q1, 2022)

(540.9m)

EBITDA (Q1, 2022)

(488.5m)

EBIT (Q1, 2022)

(558.8m)

Market capitalization (22-Jun-2022)

135.2b

Closing stock price (22-Jun-2022)

489.0

Cash (31-Mar-2022)

2.6b

EV

133.1b
PharmaEssentia's current market capitalization is NT$135.2 b.
Annual
TWDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

26.2m305.7m557.3m656.5m

Cost of goods sold

(28.4m)(61.7m)(198.5m)(151.8m)

Gross profit

455.0k255.6m400.3m529.4m

R&D expense

(785.7m)(639.6m)(922.4m)(1.3b)
Quarterly
TWDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

35.5m69.2m1.7m710.0k130.6m133.7m97.7m86.8m92.1m251.7m

Cost of goods sold

586.0k(3.7m)489.0k(1.1m)(74.6m)(19.5m)(75.6m)(69.7m)97.9m(120.7m)

Gross profit

37.9m65.7m10.3m1.2m72.0m124.8m28.6m20.3m200.5m133.2m

R&D expense

(226.6m)(165.3m)(120.8m)(157.5m)(146.7m)(252.2m)(197.3m)(267.3m)(315.5m)(258.1m)
show all
Annual
TWDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

2.2b1.4b3.2b3.5b

Accounts Receivable

23.0m199.4m450.6m466.0m

Prepaid Expenses

32.6m55.4m44.0m76.5m

Inventories

33.5m255.3m394.8m861.4m
Quarterly
TWDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

1.9b1.5b1.4b1.2b2.4b4.2b2.4b1.6b1.0b2.6b

Accounts Receivable

26.0m101.5m504.0k441.0k427.8m320.2m401.8m401.8m391.7m499.7m

Prepaid Expenses

36.1m40.3m57.3m96.1m68.9m53.2m105.4m98.5m68.2m131.5m

Inventories

33.5m83.5m184.8m322.1m389.3m468.0m467.1m539.2m629.6m974.2m
show all
Annual
TWDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(1.0b)(842.1m)(1.9b)(2.8b)

Depreciation and Amortization

58.5m137.4m174.8m227.1m

Inventories

24.1m(221.9m)(137.5m)(466.5m)

Accounts Payable

4.1m13.4m21.9m(690.0k)
Quarterly
TWDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(278.3m)(480.0m)(755.0m)(291.6m)(498.9m)(1.1b)(683.2m)(1.2b)(1.9b)(540.9m)

Depreciation and Amortization

28.5m63.1m99.9m39.2m81.9m127.6m54.7m110.4m166.2m66.3m

Inventories

(81.0k)(50.0m)(151.4m)(66.8m)(132.0m)(210.6m)(72.2m)(144.3m)(234.7m)(112.8m)

Accounts Payable

(5.3m)(4.5m)6.1m(1.0m)24.4m30.6m(32.1m)(30.8m)(46.5m)6.1m
show all
Show all financial metrics

PharmaEssentia Revenue Breakdown

Embed Graph

PharmaEssentia revenue breakdown by business segment: 100.0% from DRUG

PharmaEssentia revenue breakdown by geographic segment: 52.2% from TAIWAN, 31.3% from EUROPE, 5.5% from ASIA and 11.0% from ALL OF NORTH & SOUTH AMERICA

PharmaEssentia Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

PharmaEssentia Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

PharmaEssentia Online and Social Media Presence

PharmaEssentia's Trends

Embed Graph

PharmaEssentia News and Updates

October 12, 2020

Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered …

 PharmaEssentia Frequently Asked Questions

  • When was PharmaEssentia founded?

    PharmaEssentia was founded in 2003.

  • Who are PharmaEssentia key executives?

    PharmaEssentia's key executives are Kochung Lin, Albert Qin and Craig Zimmerman.

  • How many employees does PharmaEssentia have?

    PharmaEssentia has 190 employees.

  • What is PharmaEssentia revenue?

    Latest PharmaEssentia annual revenue is NT$656.5 m.

  • What is PharmaEssentia revenue per employee?

    Latest PharmaEssentia revenue per employee is NT$3.5 m.

  • Who are PharmaEssentia competitors?

    Competitors of PharmaEssentia include Tanvex Biopharma, Jiangsu Hansoh Pharmaceutical Group and 3sbio.

  • Where are PharmaEssentia offices?

    PharmaEssentia has offices in Burlington and Shinjuku City.

  • How many offices does PharmaEssentia have?

    PharmaEssentia has 5 offices.